Showing 41 - 60 results of 23,710 for search '(((( 50 a decrease ) OR ( 10 μ decrease ))) OR ((( 50 nn decrease ) OR ( 50 ng decrease ))))', query time: 0.74s Refine Results
  1. 41
  2. 42
  3. 43
  4. 44
  5. 45
  6. 46

    GSK343 decreased tumor stemness. by Laura V. Bownes (10276762)

    Published 2021
    “…<p>(A) COA3 and (B) COA6 PDX cells were plated as single cell suspension in serum-free, conditioned media onto 96-well low attachment plates using serial dilutions with 5000, 1000, 100, 50, 20, 10, and 1 cell per well. …”
  7. 47
  8. 48
  9. 49
  10. 50
  11. 51

    Top 10 pathways with the lowest p-value. by Rizka Fatriani (17485787)

    Published 2024
    “…Molecular docking results between PPARG and EP300 with the ten active compounds showed a binding affinity value of ≤ -5.0 kcal/mol in all dockings, indicating strong binding. …”
  12. 52
  13. 53

    Top 10 gene ontologies with the lowest p-value. by Rizka Fatriani (17485787)

    Published 2024
    “…Molecular docking results between PPARG and EP300 with the ten active compounds showed a binding affinity value of ≤ -5.0 kcal/mol in all dockings, indicating strong binding. …”
  14. 54

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  15. 55

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  16. 56
  17. 57
  18. 58

    TUDCA decreases ER stress in HOX neonatal rat lungs. by Kirkwood A. Pritchard Jr. (13449794)

    Published 2022
    “…(<b>C</b>) In IHC stain, P-IRE1α levels are decreased (40.8±3.5 A.U. <i>vs</i> 53.1±5.0 A.U., p<0.001, n = 6, 3 for each sex) in chronic hyperoxia exposed neonatal rat lungs by TUDCA. …”
  19. 59
  20. 60